ArticleFrontiers in pediatrics2026
Omalizumab demonstrates efficacy and safety in Chinese children under 12 with chronic urticaria: a case series.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Omalizumab, an anti-IgE antibody, is recommended as a second-line therapy for chronic spontaneous urticaria in patients aged ≥12 years; however, real-world evidence for its use in younger Chinese children remains limited. Therefore, this study aimed to evaluate its clinical efficacy, safety, and associated characteristics of omalizumab in this underserved pediatric population under 12 years of age. Methods: We conducted a retrospective analysis of 13 Chinese children (aged <12 years) with refractory chronic urticaria treated with omalizumab. Effectiveness was assessed by the Urticaria Activity Score over 7 days (UAS7), and safety was evaluated by monitoring adverse events. Results: Of the 13 pediatric patients (median age 5.8 years; 46.2% male), all demonstrated rapid clinical improvement within one week after the initial omalizumab dose. Oral antihistamines were successfully discontinued in all patients within four weeks, accompanied by a significant reduction in the median UAS7 score from 20.0 at baseline to 4.0 ( Conclusion: The rapid symptom control and excellent safety profile observed support omalizumab as an effective and well-tolerated therapeutic option for children under 12 with chronic urticaria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.